NJXB(SH:600682) Zheng Quan Zhi Xing·2025-05-15 08:15Core Viewpoint - The company held its 2024 Annual General Meeting, discussing various operational and financial aspects, including a slight increase in revenue but a significant decrease in net profit, alongside strategic plans for future growth in various sectors [1][21][24]. Group 1: Meeting Details - The 2024 Annual General Meeting is scheduled for May 21, 2025, at 13:30 in Nanjing [1]. - The meeting will include both on-site and online voting methods [4]. - Legal opinions will be provided by Jiangsu Taihe Law Firm during the meeting [3][4]. Group 2: Financial Performance - The company achieved an operating revenue of 6.7 billion yuan, a year-on-year increase of 1.98%, with the main business revenue accounting for 95.91% [5][21]. - The net profit attributable to shareholders was 230 million yuan, a decrease of 46.10% compared to the previous year [21][24]. - The total assets of the company reached 26.225 billion yuan, with total liabilities of 7.132 billion yuan [23]. Group 3: Business Segments - The main business sectors include commercial retail, hospitality, health and elderly care, professional technical services, pharmaceutical manufacturing, and medical services [5][21]. - The commercial sector reported a revenue of 412 million yuan, down 11.27% year-on-year [22]. - The health and elderly care sector generated 2.128 billion yuan, with a slight decrease of 0.11% [22]. Group 4: Strategic Initiatives - The company is focusing on enhancing its core business capabilities and expanding its market presence in health and elderly care services, as well as in the biomedical sector [26][29]. - Plans include upgrading retail spaces and introducing new brands to improve customer experience [29]. - The company aims to retain undistributed profits for future investments in market expansion and R&D [31]. Group 5: Governance and Compliance - The board of directors held eight meetings during the reporting period, ensuring compliance with legal and regulatory requirements [9][12]. - The independent directors actively participated in decision-making and oversight, contributing to the company's stable development [14][15]. - The company has established a robust internal control system to manage operational risks effectively [16][20]. Group 6: Future Outlook - The company anticipates continued growth in the health and elderly care market, driven by an aging population and increasing consumer demand [25][27]. - The biomedical sector is expected to expand significantly, supported by government policies promoting stem cell technology and clinical applications [26][28]. - The retail business is undergoing transformation to adapt to market changes and consumer preferences, aiming for sustainable growth [29][31].